UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)


☒	Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended June 30, 2024


☐	Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from to .

Commission File Number: 001-38905

NextCure, Inc.

(Exact name of registrant as specified in its charter)

Delaware	47-5231247
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

9000 Virginia Manor Road, Suite 200 Beltsville, Maryland	20705
(Address of principal executive offices)	(Zip Code)

(240) 399-4900

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered:
Common Stock, $0.001 par value per share	NXTC	Nasdaq Global Select Market

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☒	Smaller reporting company ☒
	Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of July 30, 2024, the registrant had 27,975,840 shares of common stock, par value $0.001 per share, issued and outstanding.

Table of Contents

NextCure, Inc.

Form 10-Q

For the Quarter Ended June 30, 2024

TABLE OF CONTENTS


		Page
PART I. FINANCIAL INFORMATION
Item 1.	Financial Statements	1
	Condensed Balance Sheets as of June 30, 2024 (unaudited) and December 31, 2023	1
	Unaudited Condensed Statements of Operations and Comprehensive Loss for the Three and Six Months Ended June 30, 2024 and 2023	2
	Unaudited Condensed Statements of Stockholders’ Equity for the Three and Six Months Ended June 30, 2024 and 2023	3
	Unaudited Condensed Statements of Cash Flows for the Six Months Ended June 30, 2024 and 2023	4
	Notes to Unaudited Condensed Financial Statements	5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	22
Item 4.	Controls and Procedures	22
Part II. OTHER INFORMATION
Item 1.	Legal Proceedings	24
Item 1A.	Risk Factors	24
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	24
Item 3.	Defaults Upon Senior Securities	24
Item 4.	Mine Safety Disclosures	24
Item 5.	Other Information	24
Item 6.	Exhibits	25
SIGNATURES		26

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

NEXTCURE, INC.

CONDENSED BALANCE SHEETS

( in thousands, except share and per share amounts)


	June 30, 2024		December 31,
	(unaudited)		2023
Assets
Current assets:
Cash and cash equivalents	$	20,848	$	13,082
Marketable securities		65,588		95,217
Prepaid expenses and other current assets		4,019		4,426
Total current assets		90,455		112,725
Property and equipment, net		6,699		9,033
Right of use assets		3,561		4,398
Other assets		1,874		1,882
Total assets	$	102,589	$	128,038
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	5,075	$	2,330
Accrued liabilities and other liabilities		5,758		4,553
Total current liabilities		10,833		6,883
Lease liabilities, long term		5,590		5,949
Other long-term liabilities		725		785
Total liabilities		17,148		13,617
Stockholders’ equity:
Preferred stock, par value of $0.001 per share; 10,000,000 shares authorized at June 30, 2024 and December 31, 2023; No shares issued and outstanding at June 30, 2024 and December 31, 2023		—		—
Common stock, par value of $0.001 per share; 100,000,000 shares authorized at June 30, 2024 and December 31, 2023; 27,975,840 and 27,903,027 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively		28		28
Additional paid-in capital		442,492		439,097
Accumulated other comprehensive loss		(86)		(222)
Accumulated deficit		(356,993)		(324,482)
Total stockholders’ equity		85,441		114,421
Total liabilities and stockholders’ equity	$	102,589	$	128,038

The accompanying notes are an integral part of these unaudited condensed financial statements.

Table of Contents

NEXTCURE, INC.

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(unaudited, in thousands, except share and per share amounts)


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2024		2023		2024		2023
Operating expenses:
Research and development	$	12,418	$	13,447	$	23,816	$	25,094
General and administrative		4,076		5,711		8,440		11,135
Restructuring and asset impairment charges		—		—		2,542		—
Total operating expenses		16,494		19,158		34,798		36,229
Loss from operations		(16,494)		(19,158)		(34,798)		(36,229)
Other income, net		1,090		1,299		2,287		2,274
Net loss	$	(15,404)	$	(17,859)	$	(32,511)	$	(33,955)
Net loss per common share - basic and diluted	$	(0.55)	$	(0.64)	$	(1.16)	$	(1.22)
Weighted-average shares outstanding - basic and diluted		27,972,744		27,828,741		27,937,892		27,801,788
Comprehensive loss:
Net loss	$	(15,404)	$	(17,859)	$	(32,511)	$	(33,955)
Unrealized gain (loss) on marketable securities		96		(122)		136		569
Total comprehensive loss	$	(15,308)	$	(17,981)	$	(32,375)	$	(33,386)

The accompanying notes are an integral part of these unaudited condensed financial statements.

Table of Contents

NEXTCURE, INC.

CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY

(unaudited, in thousands, except share data)

SEC Form 10-Q filed by NextCure Inc.